Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
With the slowdown in world economic growth, the Emergency Contraceptives industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Emergency Contraceptives market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2018, Stratagem Market Insights analysts believe that in the next few years, Emergency Contraceptives market size will be further expanded, we expect that by 2023, The market size of the Emergency Contraceptives will reach XXX million $.
Emergency contraceptives can be used after sex to stop a pregnancy before it starts. There are two main types of emergency contraception: Emergency contraceptive pills (ECPs) and copper T intrauterine device (IUD).
Increasing population is expected to propel growth of the global emergency contraceptives market over the forecast period. For instance, according to projections by Population Reference Bureau (PRB) included in the 2018 World Population Data Sheet, the world population is expected to reach 9.9 billion by 2050, up 2.3 billion or 29% from an estimated 7.6 billion people in 2018.
Moreover, increasing focus on family planning among the populace is also expected to aid in growth of the market. For instance, according to PRB’s 2019 Family Planning Data Sheet, globally, 62 percent of married women ages 15 to 49 use a method of family planning and 56 percent use a modern method.
Increasing rate of literacy is expected to offer lucrative growth opportunities for players in the global emergency contraceptives market. For instance, according to United Nations Children's Fund, globally, the youth literacy rate increased from 83% to 91% during 1985-2018. Moreover, R&D in emergency contraceptives is also expected to aid in growth of the market. For instance, in March 2020, researchers from Monash University and The Alfred Hospital, Australia, reported assessing the impact of oral contraceptive androgenicity on visuospatial and social-emotional cognition in reproductive-aged women.
However, low adoption of emergency contraceptives in emerging economies is expected to hinder growth of the global emergency contraceptives market. For instance, according to PRB’s 2019 Family Planning Data Sheet, fewer than 15% of married women of reproductive age use a modern contraceptives in Democratic Republic of the Congo.
Key Takeaways:
- Increasing population is expected to propel growth of the global emergency contraceptives market over the forecast period
- Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Evofem Biosciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel used to prevent pregnancy in females of reproductive potential for use as an on-demand method of contraception.
- Major players operating in the global emergency contraceptives market include, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, and Mankind Pharma
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.
Section 1: Definition
Section (2 3): Manufacturer Detail
Genetics
Teva Pharmaceutical
Uniprix
Gavis Pharmaceuticals
HRA Pharma
Mankind Pharma
Section 4: Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation:
- Combined estrogen and progestin pills
- Progestin-only (as Levonorgestrel) pills
- Antiprogestin (as mifepristone) pills
- Ulipristal acetate pills
Industry Segmentation:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2027)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
